Moderna tells Journal it will not enforce vaccine patents during the pandemic

/ / News

Shares of Moderna Inc. were up 1.2% in premarket trading on Thursday, after a report in The Wall Street Journal said the company would not enforce any of the seven patents it holds for its COVID-19 vaccine candidate during the pandemic. Moderna also told the Journal that it would be willing to license the patents to other organizations when the pandemic ends. Moderna’s experimental coronavirus vaccine is one of four candidates to enter Phase 3 trials so far this year. It is considered to be one of the frontrunner candidates in the race to bring to market a COVID-19 vaccine. Its stock has soared 270.0% so far this year, while the S&P 500 is up 5.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.